Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole‐induced polycystic ovary syndrome in the Sprague Dawley rats
Phytotherapy Research · 2023-09 · 37 (9) · 4018-4041
DOI: 10.1002/ptr.7860 ↗At a glance
Journal article in Phytotherapy Research, published online on 2023-05-10. Written by Rumaisa Rashid and 8 co-authors. Institution: Endocrinology Division, CSIR-Central Drug Research Institute, Lucknow, India. Major MEDLINE topics: Polycystic Ovary Syndrome, Follicular Cyst, Metformin. Cited 35 times so far (Crossref); 84 references. Funded by: Council of Scientific and Industrial Research (CSIR), New Delhi, India, Department of Health and Research, Human Resource Development, New Delhi, India, Department of Biotechnology, New Delhi, India.
Abstract (original language)
Polycystic ovary syndrome (PCOS) is most common in women of reproductive age, giving rise to androgen excess and anovulation, leading to infertility and non‐reproductive complications. We explored the ameliorating effect of naringenin in PCOS using the Sprague Dawley (SD) rat model and human granulosa cells. Letrozole‐induced PCOS rats were given either naringenin (50 mg/kg/day) alone or in combination with metformin (300 mg/kg/day), followed by the estrous cycle, hormonal analysis, and glucose sensitivity test. To evaluate the effect of naringenin on granulosa cell (hGC) steroidogenesis, we treated cells with naringenin (2.5 μM) alone or in combination with metformin (1 mM) in the presence of forskolin (10 μM). To determine the steroidogenesis of CYP‐17A1, ‐19A1, and 3βHSD2, the protein expression levels were examined. Treatment with naringenin in the PCOS animal groups increased ovulation potential and decreased cystic follicles and levels of androgens. The expression levels of CYP‐17A1, ‐19A1, and 3βHSD2, were seen restored in the ovary of PCOS SD rats' model and in the human ovarian cells in response to the naringenin. We found an increased expression level of phosphorylated‐AKT in the ovary and hGCs by naringenin. Naringenin improves ovulation and suppress androgens and cystic follicles, involving AKT activation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Endocrinology Division, CSIR-Central Drug Research Institute, Lucknow, India.
- Department of Pharmaceutical Sciences, University of Kashmir, Jammu and Kashmir, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
ORCID profiles: Rajesh Kumar Jha
Funding
- Council of Scientific and Industrial Research (CSIR), New Delhi, India
- Department of Health and Research, Human Resource Development, New Delhi, India
- Department of Biotechnology, New Delhi, India
Cite
APA
Rashid, R., Tripathi, R., Singh, A., Sarkar, S., Kawale, A., Bader, G. N., Gupta, S., Gupta, R. K., & Jha, R. K. (2023). Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole‐induced polycystic ovary syndrome in the Sprague Dawley rats. Phytotherapy Research, 37(9), 4018-4041. https://doi.org/10.1002/ptr.7860
Vancouver
Rashid R, Tripathi R, Singh A, Sarkar S, Kawale A, Bader GN, et al. Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole‐induced polycystic ovary syndrome in the Sprague Dawley rats. Phytotherapy Research. 2023;37(9):4018-4041. doi:10.1002/ptr.7860
BibTeX
@article{Rashid2023,
author = {Rashid, Rumaisa and Tripathi, Rupal and Singh, Akanksha and Sarkar, Sudarsan and Kawale, Ajaykumar and Bader, G N and Gupta, Satish and Gupta, Rakesh Kumar and Jha, Rajesh Kumar},
title = {Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole‐induced polycystic ovary syndrome in the Sprague Dawley rats},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {9},
pages = {4018--4041},
doi = {10.1002/ptr.7860}
}
EUVIMED